To this end, the second international forum on HIV and Liver Disease was convened in Jackson Hole, WY, in September 2008. The first forum, held 2 years earlier was previously summarized in HEPATOLOGY, and has been widely cited by experts in the field.1 However, the fast-moving nature of this critical health issue led to development of a second meeting, supported by grants from three institutes of the National Institutes of Health (NIH) (National Institute of Allergy and Infectious Diseases [NIAID], National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK], and the National Institute on Alcohol Abuse and Alcoholism Erlotinib mw [NIAAA]) and
by unrestricted grants provided by the pharmaceutical industry. As before, the meeting sought to bring together basic and clinical researchers representing multiple disciplines including hepatology, infectious diseases, epidemiology, virology, and drug development as well as governmental experts in health policy, research, and research funding. This document
provides a summary of key presentations and highlights the current state of knowledge and future directions this field will take. HIV prevalence in the United States is increasing due to the stable this website incidence of HIV (estimated at 53,600 cases/year in 2006) and the longer life expectancy attributable to widespread use of effective antiretroviral therapies. This pattern permits non-HIV defining processes to predominate as major causes of morbidity and mortality. New infection with
HIV is primarily transmitted from persons who do not know that they are infected with HIV, and this observation represents a significant change compared to historical data regarding HIV transmission.2 Furthermore, HIV disproportionately affects African-Americans, Hispanics, men who have sex with men (MSM), and those living in the southern United States. The rate of new infection in MSMs appears www.selleck.co.jp/products/Romidepsin-FK228.html to be increasing.3, 4 Recent recommendations from the U.S. Centers for Disease Control and Prevention to broaden screening for HIV may result in an increase in new cases referred to the hepatologist or gastroenterologist. Shared mechanisms of transmission lead to high coinfection rates with both hepatitis C virus (HCV) and hepatitis B virus (HBV) among those with HIV infection. However, rates of infection are highly variable and depend on the nature of shared risk. Current estimates of HCV disease burden suggest that between 250,000 and 300,000 individuals in the United States are coinfected with HCV and HIV.5, 6 Worldwide, rates of coinfection are highly variable. In sub-Saharan Africa, rates of HCV/HIV may be as low as 2%–3% of the HIV-infected population.6 This reflects the predominant mode of HIV transmission, heterosexual exposure, which is relatively inefficient for HCV viral spread. In contrast, reports of acute HCV infection among MSMs appear to be increasing.
Related posts:
- The GSC is an open-member international community consisting of o
- 2-5 Hepatic iron deposition in the setting of chronic liver disea
- An acute liver injury corresponds to an increase in liver test va
- A spectrum of treatment (from bleeding to liver transplantation [
- These criteria were revised recently by the international working